Anemia is the most common complication of inflammatory bowel disease (IBD). Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser ex...Anemia is the most common complication of inflammatory bowel disease (IBD). Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser extent, malabsorption of iron are the main causes of iron def iciency in IBD. There is also a variable component of anemia related to chronic inflammation. The anemia of chronic renal failure has been treated for many years with recombinant human erythropoietin (rHuEPO), which significantly improves quality of life and survival. Subsequently, rHuEPO has been used progressively in other conditions that occur with anemia of chronic processes such as cancer, rheumatoid arthritis or IBD, and anemia associated with the treatment of hepatitis C virus. Erythropoietic agents complete the range of available therapeutic options for treatment of anemia associated with IBD, which begins by treating the basis of the inflammatory disease, along with intravenous iron therapy as f irst choice. In cases of resistance to treatment with iron, combined therapy with erythropoietic agents aims to achieve near-normal levels of hemoglobin/hematocrit (11-12 g/dL). New formulations of intravenous iron (iron carboxymaltose) and the new generation of erythropoietic agents (darbepoetin and continuous erythropoietin receptor activator) will allow better dosing with the same eff icacy and safety.展开更多
A robust and versatile tool for multigene pathway assembly is a key to the biosynthesis of high- value chemicals. Here we report the rapid construction of biosynthetic pathways in Saccharomyces cerevisiae using a mark...A robust and versatile tool for multigene pathway assembly is a key to the biosynthesis of high- value chemicals. Here we report the rapid construction of biosynthetic pathways in Saccharomyces cerevisiae using a marker recyclable integrative toolbox （pUMRI） devel- oped in our research group, which has features of ready-to- use, convenient marker recycling, arbitrary element replacement, shuttle plasmid, auxotrophic marker inde- pendence, GAL regulation, and decentralized assembly. Functional isoprenoid biosynthesis pathways containing 4-11 genes with lengths ranging from -10 to -22 kb were assembled using this toolbox within 1-5 rounds of reiterative recombination. In combination with GAL- regulated metabolic engineering, high production of isoprenoids （e.g., 16.3 mg.g-1 dcw carotenoids）was achieved. These results demonstrate the wide range of application and the efficiency of the pUMRI toolbox in multigene pathway construction of S. cerevisiae.展开更多
文摘Anemia is the most common complication of inflammatory bowel disease (IBD). Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser extent, malabsorption of iron are the main causes of iron def iciency in IBD. There is also a variable component of anemia related to chronic inflammation. The anemia of chronic renal failure has been treated for many years with recombinant human erythropoietin (rHuEPO), which significantly improves quality of life and survival. Subsequently, rHuEPO has been used progressively in other conditions that occur with anemia of chronic processes such as cancer, rheumatoid arthritis or IBD, and anemia associated with the treatment of hepatitis C virus. Erythropoietic agents complete the range of available therapeutic options for treatment of anemia associated with IBD, which begins by treating the basis of the inflammatory disease, along with intravenous iron therapy as f irst choice. In cases of resistance to treatment with iron, combined therapy with erythropoietic agents aims to achieve near-normal levels of hemoglobin/hematocrit (11-12 g/dL). New formulations of intravenous iron (iron carboxymaltose) and the new generation of erythropoietic agents (darbepoetin and continuous erythropoietin receptor activator) will allow better dosing with the same eff icacy and safety.
基金This work was financially supported by the National Natural Science Foundation of China （Grant Nos. 21406196 and 21576234）, Zhejiang Provincial Natural Science Foundation of China （Grant No. LQI4B060005）, and Qianiiang Talents Project.
文摘A robust and versatile tool for multigene pathway assembly is a key to the biosynthesis of high- value chemicals. Here we report the rapid construction of biosynthetic pathways in Saccharomyces cerevisiae using a marker recyclable integrative toolbox （pUMRI） devel- oped in our research group, which has features of ready-to- use, convenient marker recycling, arbitrary element replacement, shuttle plasmid, auxotrophic marker inde- pendence, GAL regulation, and decentralized assembly. Functional isoprenoid biosynthesis pathways containing 4-11 genes with lengths ranging from -10 to -22 kb were assembled using this toolbox within 1-5 rounds of reiterative recombination. In combination with GAL- regulated metabolic engineering, high production of isoprenoids （e.g., 16.3 mg.g-1 dcw carotenoids）was achieved. These results demonstrate the wide range of application and the efficiency of the pUMRI toolbox in multigene pathway construction of S. cerevisiae.
